Cajuput

Cajuput (Cajeput): A Comprehensive Reference

1. Identity and Botanical Classification

Nomenclature and Taxonomy

Cajuput oil (also spelled cajeput) is a volatile oil obtained by distillation from the leaves of the myrtaceous trees Melaleuca leucadendra, Melaleuca cajuputi, and probably other Melaleuca species. Melaleuca cajuputi, commonly known as cajuput or white samet, is a plant in the myrtle family, Myrtaceae, and is widespread in Australia, Southeast Asia, New Guinea, and the Torres Strait islands. Melaleuca cajuputi was first formally described in 1809 by Thomas Powell in the Pharmacopoeia of the Royal College of Physicians of London, with a reference to an earlier (1747) description by Rumphius in Herbarium Amboinense. The specific epithet (cajuputi) is probably from the Indonesian or Malay name for the plant, kayu putih, meaning "white tree."

In Indonesia, Melaleuca is commonly referred to as "Kayu Putih," and its essential oil—commonly known as cajuput oil—is primarily derived from M. cajuputi and M. leucadendra (or M. leucadendron). However, early references to M. leucadendra or M. leucadendron in cajuput oil production often actually referred to M. cajuputi. Commercial cajuput oil is mostly obtained from Melaleuca cajuputi subsp. cajuputi.

Cajuput also goes by the names cajuput, kajuput, melaleuca cajuputi, and minyak kayu putih. Additional synonyms documented in the literature include cajuputi aetheroleum, aceite de cajuput, essence de cajuput, kayaputi (India), River Tea Tree, Weeping Tea Tree, Swamp Tea Tree, and Punk Tree.

Botanical Description and Natural Habitat

Melaleuca cajuputi is usually a medium to large tree, often growing to 35 metres (100 ft) and sometimes to 46 metres (200 ft) with grey, brownish or whitish papery bark. The new growth is silky-hairy, becoming glabrous as it matures. The leaves are arranged alternately, 40–140 millimetres (2–6 in) long and 7.5–60 millimetres (0.3–2 in) wide, tapering at both ends. The flowers are white, cream or greenish-yellow, mostly in dense spikes at the ends of the branches.

The trees yielding the oil are found throughout Maritime Southeast Asia and over the hotter parts of the Australian continent. The majority of the oil is produced on the Indonesian island of Sulawesi. Cajuput is primarily sourced from countries such as Indonesia, Malaysia, Vietnam, and Papua New Guinea, where the climatic conditions, including high humidity and warm temperatures, are conducive to its growth. While M. cajuputi is widely cultivated for commercial oil production, M. leucadendra is typically found in South and Central Kalimantan, Sumatra, Java, Maluku, Papua, and peatland regions.

Extraction and Common Forms

The oil is prepared from cajeput leaves and twigs macerated in water, and steam-distilled after fermenting for a night. The resulting oil is extremely pungent, flammable, and has the odor of a mixture of turpentine, eucalyptus and camphor. More specifically, the leaves and twigs of the trees are harvested on a hot and dry day and then macerated in water into a thick pulp. The pulp is fermented overnight before undergoing the steam distillation process to get the final product — cajeput essential oil.

This oil is a pale yellow liquid and contains up to 60% 1,8-cineole, the main antimicrobial component. Common commercial preparations include the neat essential oil, as well as formulated products such as liniments, balms, chest rubs, gargles, throat lozenges, inhalants, and decongestant preparations. It is an ingredient in some liniments to relieve sore muscles, such as Tiger Balm, and the Indonesian traditional medicine known as "Minyak Telon." An Indonesian functional food known as "Cajuputs candy" (CC) utilizes the bioactivity of Melaleuca cajuputi essential oil (MCEO) to maintain oral cavity health.

2. Traditional and Historical Use

Southeast Asia: Indonesia and Malaysia

Cajuput oil from M. cajuputi has been used in medicine since the eighteenth century as an antiseptic agent, and its effect is comparable to that of tea tree oil from M. alternifolia. Melaleuca cajuputi Powell essential oil (MCEO) is widely used in Malay traditional medicine for the treatment of stomach cramps, cough, acne, insect bites, thrush problems and many more.

For hundreds of years, people in Indonesia and Malaysia have used cajeput oil for almost everything, calling it a "general wellness oil." Parents would often rub a little bit of the oil on a child's stomach if they felt bloated. They would rub it on their chests during the rainy season to keep them warm. It was even used to help with toothaches by putting a tiny bit on the gums.

In Southeast Asia, Melaleuca cajuputi is used as a fuel and for making charcoal. It is used on a small scale for supporting columns, frames, and floorboards in house construction and for fences. The bark has been used as roofing material and a sealant in boat construction, including as a caulking material for boats in Indonesia.

Australia: First Nations Peoples

Indigenous Australian people used the leaves of this species to treat aches and pains and inhaled vapours from the crushed leaves to treat respiratory infections. Cajeput leaves were traditionally used by the First Nations people of Australia on Groote Eylandt (off the coast of Northern Territory) for their pain-relieving properties. It is believed the Anindilyakwa people of the region crushed the leaves in their hands and rubbed them onto the affected area.

India and Thailand

In India, cajeput is known as kayaputi and has historically been used for stomach discomfort, rheumatism, infections, and as a natural insect deterrent. In Thailand, the leaves are used to make a herbal tea as a treatment for a range of medical problems.

Broader Ethnomedicinal and Historical Preparations

In many parts of Asia, the oil is used as a liniment and inhalant. Ancient healers and indigenous communities harnessed its potent properties to address respiratory issues such as coughs, colds, and bronchitis, often by inhaling the steam from cajeput-infused water or applying diluted oil to the chest. In traditional balms and liniments, cajeput is often mixed with menthol or camphor, creating soothing applications for headaches, insect bites, and minor skin irritations.

3. Key Constituents and Active Compounds

Primary Chemical Profile

GC-MS analysis of M. cajuputi oil identified 1,8-cineole (64.43%) as the principal component, followed by α-pinene (5.48%), α-terpineol (5.44%), β-caryophyllene (3.82%), γ-terpinene (3.24%), α-humulene (1.81%), β-selinene (1.28%), α-selinene (1.12%), β-pinene (1.11%), and terpinolene (1.04%). However, chemical composition varies considerably by geographic origin and botanical source. Oil of M. cajuputi Powell contains mostly eucalyptol (1,8-cineol) (52–57%) with lesser amounts (5–13%) of D-limonene, 4-terpineol, and caryophyllene.

The chemical profile of the oil varies significantly depending on its botanical source. The main bioactive compounds of MCEO include terpenes, esters, aldehydes, and alkenes. The other dominant compounds in the oils of Melaleuca leucadendron are mostly monoterpenes, such as D-limonene, α-terpineol, β-caryophyllene, α-pinene, eugenol, β-pinene, globulol, γ-terpineol, γ-terpinene, 2-pentanone, β-eudesmene, α-humulene, and 2,4-pentanediol. The dominant components of Melaleuca cajuputi oil are similar to those of Melaleuca leucadendron, but sesquiterpenes (α-selinene and α-gurjunene) have additionally been detected.

Terpineols have been isolated from a variety of sources such as cardamom, cajuput oil, pine oil, and petitgrain oil. The EFSA Panel stipulated that for regulatory safety conclusions, the following conclusions apply only to cajuput oil in which methyleugenol, estragole, and safrole are not detected (LOD 0.01 mg/kg), and for which 1,8-cineole, α-terpineol, and d-limonene are the main constituents.

The Major Active Constituent: 1,8-Cineole (Eucalyptol)

The mucolytic monoterpene 1,8-cineole (eucalyptol), the major constituent of eucalyptus species, is well known for its anti-inflammatory, antioxidant, bronchodilatory, antiviral, and antimicrobial effects. 1,8-Cineole (also known as eucalyptol) is a monoterpenoid oxide present in the essential oil form of the plant families of Myrtaceae, Lamiaceae, and Zingiberaceae.

After oral administration, 1,8-cineole is absorbed in the small intestine and subsequently metabolized in the liver by human cytochrome P450 enzymes (CYP3A4/5). Its primary metabolites, 2-alpha-hydroxy- and 3-alpha-hydroxy-1,8-cineole, are excreted through urine. In addition to its systemic availability in the bloodstream, 1,8-cineole can reach the bronchial system and be exhaled through the peripheral airways.

The antimicrobial effect of (−)-linalool, (−)-terpinen-4-ol, (±)-α-terpineol, and 1,8-cineole as isolated constituents of cajuput oil has been demonstrated.

4. Mechanisms of Action

Anti-inflammatory Mechanisms

The main protective antiviral, anti-inflammatory, and mucolytic mechanisms of 1,8-cineole are the induction of interferon regulatory factor 3 (IRF3), the control of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), along with decreasing mucin genes (MUC2, MUC19).

1,8-Cineole, a terpenoid oxide present in many plant essential oils, displays an inhibitory effect on some types of experimental inflammation in rats, including paw oedema induced by carrageenan and cotton pellet-induced granuloma. Cineole also inhibits, in mice, the acetic acid-induced increase in peritoneal capillary permeability and the chemical nociception induced by intraplantar formalin and intraperitoneal acetic acid. Activity was present in these tests at an oral dose range of 100–400 mg/kg. These results, taken together with recent reports describing the inhibitory effects of cineole on the formation of prostaglandins and cytokines by stimulated monocytes in vitro, may provide additional evidence for its potential beneficial use in therapy as an anti-inflammatory and analgesic agent.

In the formalin test, the antinociceptive effect of cineole was not reversed by pretreatment of mice with naloxone (1 mg/kg, s.c.), a mu-opioid receptor antagonist, suggesting the involvement of a non-opioid mechanism.

Clinical studies have demonstrated that 1,8-cineole exhibits steroid-like anti-inflammatory effects by inhibiting arachidonic acid metabolism and cytokine production.

Respiratory Mechanisms

Similar to other aromatic oils, 1,8-cineole is commonly used to treat respiratory tract infections due to its ability to increase the ciliary beat frequency in the mucus membrane and its bronchodilating and anti-inflammatory properties, as evidenced by preclinical studies.

In vitro studies found strong evidence that 1,8-cineole controls inflammatory processes and mediator production of infection- or inflammation-induced mucus hypersecretion by its action as an anti-inflammatory modifier rather than a simple mucolytic agent.

Myorelaxant and Spasmolytic Mechanisms

The 1,8-cineole exerts its myorelaxant properties by inhibiting calcium channels in smooth muscle. It seems that 1,8-cineole has good potential for producing antispasmodics or gastrointestinal motility modulators.

Anti-infective Mechanisms

In an LPS-induced alveolar macrophage inflammation model, pre-treatment with eucalyptus oil significantly reduced (P ≤ 0.01 or 0.05) the pro-inflammatory mediators TNF-α, IL-1 (α and β), and NO, albeit at a variable rate and extent; 1,8-cineole diminished IL-1 and IL-6.

1,8-Cineole has been shown to penetrate E. coli biofilm, which could be enhanced under osmotic stress.

5. Scientific Evidence by Area of Use

5.1 Respiratory Health (Bronchitis, Asthma, COPD, Sinusitis)

This is the area where the most substantial clinical evidence exists, though it pertains primarily to 1,8-cineole as an isolated compound rather than to cajuput oil specifically. Cajuput oil is one of several natural sources of 1,8-cineole, and preclinical and mechanistic research on its constituent directly informs the biological plausibility of the whole oil's respiratory applications.

As an isolated compound, 1,8-cineole is known for its mucolytic and spasmolytic action on the respiratory tract, with proven clinical efficacy. It has also shown therapeutic benefits in inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD). This clinical evidence refers to its anti-inflammatory and anti-oxidant mode of action, which has been proven in numerous pre-clinical studies.

A double-blind, placebo-controlled trial provided clinical evidence supporting the anti-inflammatory efficacy of 1,8-cineole in asthma management. The trial involved 32 patients with severe asthma and significant glucocorticoid dependence. Patients treated with 1,8-cineole experienced an average 36% reduction in oral glucocorticoid dosage (approximately 3.75 mg/day), compared to a 7% reduction (approximately 0.91 mg/day) in the placebo group. Furthermore, those receiving 1,8-cineole maintained stable lung function and had significantly lower cumulative glucocorticoid exposure than the placebo group.

A randomized study in acute bronchitis (n = 242) with 1,8-cineole over 10 days showed significant improvements after 4 days in the bronchitis severity-sum score compared to placebo. Concomitant therapy with 1,8-cineole (two capsules of 100 mg three times daily) was also studied in a placebo-controlled study (n = 242) in COPD (GOLD II–III) with a primary outcome of reduction of exacerbations, and secondary outcomes of changes in lung function, respiratory symptoms, and quality of life scores during 6 months. Basic medication consisted of LABA, inhaled corticosteroids (ICS), anticholinergics, and theophylline.

In Germany, Soledum™ enteric-coated capsules, which contain 100 mg or 200 mg (forte) of 1,8-cineole (CNL-1976) per capsule, have been registered as authorized medicinal products for several years and are utilized in treating inflammatory respiratory disorders such as the common cold, bronchitis, sinusitis, bronchial asthma, and COPD.

Evidence strength: For the isolated constituent 1,8-cineole in respiratory disease, evidence is moderate, supported by multiple double-blind placebo-controlled trials. For cajuput oil as a whole product in these same conditions, direct human clinical trials are essentially absent; the biological plausibility rests on its high 1,8-cineole content.

5.2 Antimicrobial Activity

Scientific research on MCEO has revealed a wide range of pharmacological activities, such as contact and fumigant toxicity, repellence, and antibacterial activity, among others.

One in vitro study demonstrated that Melaleuca cajuputi essential oils exhibit significant antibacterial activity against MRSA, as evidenced by concentration-dependent growth inhibition, favorable MIC and MBC values, and pronounced bactericidal effects. The MIC values (3.13–12.5%) and MBC values (3.13–25%) obtained in the study confirm the antibacterial potency. Natural extracts with MIC values below 8 mg/mL are considered promising antibacterial agents. Although the MIC values for M. cajuputi essential oils are higher than those of conventional antibiotics, they are comparable to or better than those of many other essential oils studied against MRSA and S. aureus.

GC-MS analysis identified alloaromadendrene and other major compounds as key bioactive constituents, with molecular docking revealing strong interactions between selected terpenoids, particularly alloaromadendrene, and MRSA virulence proteins. The essential oils also modulated key virulence-associated genes, significantly suppressing mecA, seb, fnbA, and tsst-1, suggesting their potential to attenuate pathogenicity through interference with gene expression.

The synergistic antimicrobial activities of blended essential oil preparations composed of eucalyptus, rosemary, patchouli, pine, and cajuput oils were evaluated against various pathogenic microorganisms. They exhibited antimicrobial activity in the agar disc diffusion assay against the Gram-positive bacteria Staphylococcus aureus and S. epidermidis, the Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa, and the yeast Candida albicans.

Essential oils from Eucalyptus globulus with 1,8-Cineol as the main metabolite (65.83%) showed antimicrobial activity against Streptococcus mutans even in biofilm cultures, emulating dental plaque conditions.

Evidence strength: Antimicrobial activity has been demonstrated extensively in vitro against a range of clinically relevant pathogens. There are no controlled human clinical trials establishing antimicrobial efficacy of cajuput oil for any specific human infection.

5.3 Antifungal Activity

At a concentration of 0.4–0.6%, cajuput oil inhibits the growth of yeasts, such as C. albicans, C. vaginalis, and C. glabrata, and molds, such as Aspergillus niger and Penicillium notatum.

One study aimed to evaluate the antifungal activity of Thai cajuput oil, its synergism with fluconazole, and its effect on efflux-pump gene expression in fluconazole-resistant C. albicans clinical isolates. Findings supported the theory that Thai cajuput oil may inhibit the growth of C. albicans and reduce the expression of genes that play an important role in fluconazole resistance in C. albicans.

Evidence strength: Antifungal activity has been shown in vitro, including against drug-resistant strains. No human clinical trials on cajuput oil for fungal infections are available.

5.4 COVID-19 Adjuvant Therapy (Pilot Clinical Evidence)

The efficacy of Melaleuca cajuputi oil as an adjuvant to the standard treatment of COVID-19 patients was assessed in a randomized clinical trial. A total of 127 COVID-19 patients aged ≥ 18–60 years with mild and moderate symptoms were treated at the Bhayangkara Brimob Hospital from November 2020 to February 2021. All patients received standard therapy, with cajuput oil (n = 67) or without cajuput oil (n = 60), for 7 days. The study protocol was approved by the Ethics Committee of the Bhayangkara Brimob Hospital.

Evidence strength: This constitutes a single small-scale randomized clinical study conducted at a single center in Indonesia. The study is preliminary; results should not be generalized without replication in larger, multi-center trials.

5.5 Insecticidal and Mosquito Larvicidal Activity

Assessment of the phytochemical, biochemical, and insecticidal properties of the chemical constituents of cajeput oil showed that Melaleuca cajuputi essential oil may exhibit mosquito larvicidal properties against Anopheles stephensi larvae (second–fourth instar) at 24 hours post-treatment. At 24 hours post-exposure, the essential oil resulted in a significant decrease in detoxifying enzymes.

Melaleuca leucadendron, Melaleuca quinquenervia, and M. cajuputi have been reported as adulticides and repellents.

Evidence strength: Primarily laboratory bioassay data; no field-efficacy human studies.

5.6 Neurological and Anxiolytic/Antidepressant Activity (Preclinical)

Preliminary studies showed that Melaleuca cajuputi essential oil (MCEO) contained several phytochemicals with antidepressant and anxiolytic properties. A study was designed to evaluate the antidepressant and anxiolytic effects of MCEO on a chronic immobilization stress (CIS)-induced mouse model using eight groups of male Swiss albino mice. All mice groups except the control were subjected to a 2-hour CIS procedure for 15 days. All MCEO treatments were administered through the inhalation route.

Cineole demonstrated a significant inhibitory effect on locomotion and also potentiated the pentobarbital sleeping time in mice, indicating a plausible depressant effect on the central nervous system.

Evidence strength: Strictly preclinical (animal model). No human trials have evaluated cajuput oil for anxiety or depression.

5.7 Oral Health

An Indonesian functional food, "Cajuputs candy," utilizes the bioactivity of Melaleuca cajuputi essential oil (MCEO) to maintain oral cavity health. In vitro evidence showing antimicrobial activity against oral pathogens, including Streptococcus mutans and Candida species, provides a biological rationale for this application, but formal human clinical trial evidence specific to cajuput oil in oral health is limited.

5.8 Analgesic and Musculoskeletal Applications

Cajuput oil has a long traditional use as a topical analgesic and counterirritant. It is frequently employed externally as a counterirritant — applying a substance to create mild inflammation in one location with the goal of lessening pain and inflammation in another location. The preclinical anti-nociceptive and anti-inflammatory evidence for 1,8-cineole (described in Section 4 above) provides mechanistic support, but no controlled human trials of cajuput oil specifically for musculoskeletal pain have been identified.

5.9 Antioxidant Activity

These findings suggest that cajuput oil has potential as a natural antioxidant and antibacterial agent. The antioxidant capacity of cajuput essential oils was determined by three different in vitro assays (DPPH radical, TBARS, and ABTS radical cation), and significant activities were evidenced for all of them.

Evidence strength: Antioxidant activity has been demonstrated in vitro. No human clinical evidence is available for cajuput oil specifically.

6. Body Systems and Health Areas

• Respiratory system: Use as an expectorant, mucolytic, bronchodilator, and inhalant for coughs, colds, bronchitis, sinusitis, and obstructive airway diseases. Supported by preclinical and clinical evidence for the key constituent 1,8-cineole.
• Musculoskeletal system: Topical use as a counterirritant and analgesic for muscle and joint pain, rheumatism. Supported by traditional use, in vitro, and animal anti-nociceptive data.
• Integumentary (skin) system: Use as an antiseptic for minor wounds, acne, and skin infections. Supported by in vitro antimicrobial and antifungal data.
• Gastrointestinal system: Traditional use for stomach cramps, bloating, and as a laxative/antispasmodic. Mechanistic support from calcium-channel inhibition data for 1,8-cineole; no clinical trials specifically on cajuput.
• Oral cavity: Applied in functional foods and oral rinses to suppress oral pathogens. In vitro evidence exists; clinical evidence is limited.
• Immune/infectious disease: Studied as an adjuvant therapy in COVID-19; broad in vitro antimicrobial spectrum.
• Central nervous system: Preclinical anxiolytic and sedative-like properties described in animal models only.
• Entomological (pest control): Larvicidal and adulticide/repellent activity demonstrated in laboratory bioassays.

7. Dosage Forms and Reported Dosages

Cajuput oil is commercially available as a neat essential oil, in diluted topical preparations, and as a constituent of compound products. No standardized human dosage has been established for cajuput oil itself. Dosages documented in the scientific literature relate primarily to its constituent 1,8-cineole:

• Concomitant therapy with 1,8-cineole was studied at two capsules of 100 mg three times daily (total 600 mg/day) in the COPD placebo-controlled trial.
• In an ex vivo study of asthma patients, 1,8-cineole was administered at 3 × 200 mg/day, with measurements taken after three days of treatment and four days after discontinuation.
• In animal anti-inflammatory and anti-nociceptive studies, activity of cineole was present at an oral dose range of 100–400 mg/kg.
• In the COVID-19 adjuvant trial, all patients in the treatment arm (n = 67) received standard therapy with Melaleuca cajuputi oil for 7 days; precise dosage of the oil itself was not specified in the published abstract.

In Germany, Soledum™ enteric-coated capsules containing 100 mg or 200 mg (forte) of 1,8-cineole per capsule are registered medicinal products for respiratory disorders. These products use highly purified 1,8-cineole, not whole cajuput oil.

MCEO has huge potential for pharmaceutical and nutraceutical applications, but comprehensive toxicity studies must be conducted to ensure safety. Research on pharmacokinetics and potential drug interactions with standard-of-care medications is still limited, which calls for additional studies, particularly in humans.

8. Safety Considerations and Interactions

Regulatory Classification

The EFSA FEEDAP Panel concludes that cajuput oil should be considered as irritant to skin and eyes, and as a dermal and respiratory sensitiser. The essential oil under assessment should be considered an irritant to skin and eyes, and as a dermal and respiratory sensitiser.

Skin Irritation

Cajuput/cajeput/Melaleuca leucadendron oil is a type of essential oil widely known and used by Indonesians for infants, children, and the elderly. It is included in telon oil compositions (±42%). Excessive application of cajeput oil and telon oil may lead to skin irritation. A safety data sheet for cajuput essential oil classifies it as Skin Corrosion/Irritation Category 2 and Sensitization Skin Category 1 under EU CLP Regulation EC No. 1272/2008.

Use in Children and Infants

Tisserand and Young (Essential Oil Safety, 2nd ed.) indicate that due to the 1,8-cineole content, cajeput oil may cause CNS and breathing problems in young children. This is consistent with known risks of high-cineole essential oils applied to the face or respiratory tract of infants.

Pharmacokinetics and CYP Enzyme Interactions

1,8-Cineole, the dominant constituent of cajuput oil, is absorbed in the small intestine and subsequently metabolized in the liver by human cytochrome P450 enzymes (CYP3A4/5). Its primary metabolites are excreted through urine. Because CYP3A4 is a major drug-metabolizing enzyme, there is a theoretical potential for interactions with co-administered drugs metabolized by the same pathway, though specific interaction studies with cajuput oil as a whole product have not been identified in the peer-reviewed literature. Research on pharmacokinetics studies and potential drug interactions with standard-of-care medications is still limited, which calls for additional studies, particularly in humans. Further assessments and clinical trials should be performed before it can be integrated into medicinal practices.

Reproductive Toxicity

A safety data sheet (SDS) for cajuput essential oil classifies it as Reproductive Toxicity Category 2 based on available data under EU GHS criteria, indicating a suspected reproductive hazard, though data specific to human exposures are not well established.

Aspiration Hazard

Cajuput essential oil is classified as Aspiration Hazard Category 1 under EU CLP Regulation, meaning oral ingestion with subsequent aspiration into the lungs poses a serious risk, as is common to most volatile essential oils.

Contaminant Concerns: Methyleugenol, Estragole, Safrole

Cajuput oil from the fresh leaves of Melaleuca cajuputi Powell and Melaleuca leucadendra (L.) L. may be produced from plants of different geographical origins, resulting in preparations with different composition and toxicological profiles. The EFSA FEEDAP Panel specifically required that safe conclusions apply only to oils free from the genotoxic/carcinogenic compounds methyleugenol, estragole, and safrole, highlighting the importance of verified chemical profiling for commercial products.

Flammability

The resulting oil is extremely pungent and flammable, with the odor of a mixture of turpentine, eucalyptus, and camphor.

Overall Safety Profile

While research suggests there are health benefits, the FDA does not monitor or regulate the purity or quality of essential oils. It is important not to replace proven measures with essential oils and other alternative methods that need further clinical studies and human trials. Further assessments and clinical trials should be performed before MCEO can be integrated into medicinal practices.

References

• Wikipedia: Melaleuca cajuputi
• Wikipedia: Cajeput oil
• Borneo Journal of Resource Science and Technology: Melaleuca cajuputi Powell Essential Oil: A Review of Botanical, Phytochemical and Pharmacological Properties
• PMC: New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma (Juergens et al., 2020)
• PMC: Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole
• PubMed: Anti-inflammatory and antinociceptive effects of 1,8-cineole — a terpenoid oxide present in many plant essential oils
• ScienceDirect: 1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases (Biomedicine & Pharmacotherapy, 2023)
• PMC: Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation
• PMC: Modes of Action of 1,8-Cineol in Infections and Inflammation
• PubMed: Antimicrobial Constituents and Effects of Blended Eucalyptus, Rosemary, Patchouli, Pine, and Cajuput Essential Oils
• PMC: Antifungal Activity of Thai Cajuput Oil and Its Effect on Efflux-Pump Gene Expression in Fluconazole-Resistant Candida albicans Clinical Isolates
• PMC: Biocontrol efficacy of cajeput oil against Anopheles stephensi L. mosquito and its effect on non-target species
• MDPI Antibiotics: Unveiling the Antibacterial Potential of Melaleuca cajuputi Essential Oils Against MRSA (2026)
• PMC: Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial
• ScienceDirect: Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial (Respiratory Medicine, 2003)
• PubMed: Anti-inflammatory effects of eucalyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo
• EFSA Journal: Safety and efficacy of cajuput oil as a feed additive for all animal species (EFSA FEEDAP Panel, 2024)
• PMC: EFSA Panel FEEDAP Opinion on cajuput oil safety and efficacy (2024)
• Journal of Applied Pharmaceutical Science: The effects of Melaleuca cajuputi oil on COVID-19 patients
• PMC: HPTLC Analysis and Chemical Composition of Selected Melaleuca Essential Oils
• ResearchGate: Antifungal Activity of Thai Cajuput Oil and Efflux-Pump Gene Expression in Fluconazole-Resistant Candida albicans
• Frontiers in Immunology: Anti-inflammatory effects of 1,8-cineol via NF-κB/COX-2 pathway in BEAS-2B cells (2026)
• Natural Resources for Human Health: Exploring the essential oil from wild Melaleuca leucadendra
• ResearchGate: Therapeutic Potential of Cajeput Oil in Muscle Health: a Mini-review through a Bibliometric Approach (2025)
• ResearchGate: Antidepressant and anxiolytic effects of Melaleuca cajuputi essential oil on CIS-induced mice
• Universitas Indonesia: The comparison of skin irritation level between topical applications of cajeput oil and telon oil
• ResearchGate: Profile of the Indonesian Essential Oil from Melaleuca cajuputi
• Wikipedia: Terpineol